|
| Status |
Public on Jan 07, 2016 |
| Title |
Response and resistance to BET bromodomain inhibitors in triple negative breast cancer |
| Organism |
Homo sapiens |
| Experiment type |
Genome binding/occupancy profiling by high throughput sequencing
Expression profiling by high throughput sequencing
|
| Summary |
This SuperSeries is composed of the SubSeries listed below.
|
| |
|
| Overall design |
Refer to individual Series
|
| |
|
| Citation(s) |
26735014 |
| |
| Submission date |
Nov 24, 2014 |
| Last update date |
May 15, 2019 |
| Contact name |
Kornelia Polyak |
| E-mail(s) |
kornelia_polyak@dfci.harvard.edu
|
| Phone |
617-632-2106
|
| Organization name |
Dana-Farber Cancer Institute
|
| Department |
Medical Oncology
|
| Lab |
Polyak
|
| Street address |
450 Brookline Ave
|
| City |
Boston |
| State/province |
MA |
| ZIP/Postal code |
02215 |
| Country |
USA |
| |
|
| Platforms (2) |
| GPL11154 |
Illumina HiSeq 2000 (Homo sapiens) |
| GPL18573 |
Illumina NextSeq 500 (Homo sapiens) |
|
| Samples (65)
|
|
| This SuperSeries is composed of the following SubSeries: |
| GSE63284 |
Response and resistance to BET bromodomain inhibitors in triple negative breast cancer [Chem-Seq] |
| GSE63581 |
Response and resistance to BET bromodomain inhibitors in triple negative breast cancer [ChIP-Seq] |
| GSE63582 |
Response and resistance to BET bromodomain inhibitors in triple negative breast cancer [RNA-Seq] |
|
| Relations |
| BioProject |
PRJNA268317 |
Less...
More...